Zyvox, Linezolid News

Based in Chapel Hill, North Carolina, Cempra Holdings scheduled a $72 million IPO with a market capitalization of $188 million at a price range mid-point of $12 for Thursday, February 2, 2012.

Trius Therapeutics' tedizolid is a novel and game-changing treatment of acute bacterial skin and skin structure infection ). Tedizolid is an intravenous and orally administered second-generation oxazolidinone used to treat serious gram-positive infections such as methicillin-resistant Staphylococcus aureus - an infection that is increasingly ... (more)

Trius Therapeutics is a development stage pharmaceutical company with a very promising antibiotic in Phase III clinical trials.

Trius Therapeutics, Inc. announced today that it has earned a $5 million milestone payment from Bayer Healthcare for the achievement of all efficacy and safety objectives in the TR701-112 Phase 3 pivotal study which tested the oral dosage form of tedizolid phosphate versus the comparator linezolid in patients with acute bacterial skin and skin ... (more)

A new report from GBI Reserch available from Reportlinker.com,A "Hospital-Acquired Bacterial Infections Market to 2017,"A predicts that this market will decline at a negative CAGR of 3.4 percent in the forecast period of 2010 to 2017.